Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Iovance Biotherapeutics Inc (NQ: IOVA ) 11.89 +0.02 (+0.21%) Streaming Delayed Price Updated: 1:05 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Iovance Biotherapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics April 05, 2024 These companies are in the early days of their growth stories. Via The Motley Fool 2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street March 26, 2024 Find out why investment banks up and down Wall Street have big expectations for these stocks. Via The Motley Fool Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) March 22, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire 10 Health Care Stocks With Whale Alerts In Today's Session March 19, 2024 Via Benzinga Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics March 13, 2024 Via Benzinga (IOVA) - Analyzing Iovance Biotherapeutics's Short Interest March 01, 2024 Via Benzinga Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity February 29, 2024 Via Benzinga Iovance Biotherapeutics: Q4 Earnings Insights February 28, 2024 Via Benzinga 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead March 18, 2024 This company's growth story is about to get moving with gusto. Via The Motley Fool Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know March 14, 2024 Via Benzinga Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know March 07, 2024 Via Benzinga 1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? March 07, 2024 Its revenue is set to grow, and one of its trials is no longer paused. Via The Motley Fool Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst March 06, 2024 With its first approval in hand, attention is now on the top line. Via The Motley Fool Iovance Biotherapeutics's Earnings: A Preview February 27, 2024 Via Benzinga Is Iovance a Buy After Its First Regulatory Win? February 25, 2024 Iovance Biotherapeutics has found a new way to treat cancer. Via The Motley Fool Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics February 23, 2024 Via Benzinga Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer March 04, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Could Iovance Biotherapeutics Stock Help You Become a Millionaire? March 02, 2024 Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio? Via The Motley Fool Iovance Biotherapeutics to Present at Upcoming Conferences March 01, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire Why Iovance Biotherapeutics Stock Got Trounced on Thursday February 29, 2024 A robust rally ended abruptly with the publication of the company's latest fundamentals. Via The Motley Fool Iovance Biotherapeutics Unusual Options Activity For February 22 February 22, 2024 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session February 29, 2024 Via Benzinga Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy? February 29, 2024 More gains might be on the way for this high-flying biotech stock. Via The Motley Fool Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates February 28, 2024 From Iovance Biotherapeutics, Inc. Via GlobeNewswire 3 Stocks Flashing Recent Insider Buying Signals February 27, 2024 One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company. Via InvestorPlace 3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 February 26, 2024 Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. Via InvestorPlace 1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street February 26, 2024 A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof. Via The Motley Fool This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst February 23, 2024 It has good news in hand and plenty of room to grow. Via The Motley Fool 2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value February 23, 2024 These two businesses have viable paths to making investors richer -- possibly soon. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.